# Safety Study of SGN-CD70A in Cancer Patients

> **NCT02216890** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 38 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Mantle-Cell Lymphoma
- Diffuse, Large B-Cell, Lymphoma
- Follicular Lymphoma, Grade 3

## Interventions

- **DRUG:** SGN-CD70A

## Key facts

- **NCT ID:** NCT02216890
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2017-02-15
- **Final completion:** 2017-02-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216890, "Safety Study of SGN-CD70A in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02216890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*